Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Amount
- $1,500,000
- Closes
- Nov 5, 2027 (in 386 days)
Similar opportunities open now
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 19, 2026 (in 35 days)
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses May 2028Up to $1M
- First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Focused Technology Research and Development (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Jan 2028
Classification and identifiers
- Solicitation number
- PAR-25-297
- Assistance listing (CFDA)
- 93.866
Amount
$1,500,000
Who can apply
State government agencies, Public colleges and universities, Private colleges and universities, Small businesses, and Nonprofits, including small and volunteer-run organizations can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defi...
About this opportunity
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to ...